Intellia Therapeutics (NTLA) Tops Q1 EPS by 26c

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.12), $0.26 better than the analyst estimate of ($1.38). Revenue for the quarter came in at $28.94 million versus the consensus estimate of $10.65 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• JPMorgan Downgrades HCL Technologies (HCLT:IN) to Underweight
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat